This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $759,974 to Washington State University to develop a novel technique for introducing mutations in the native VlsE gene of Borrelia burgdorferi. The objective is to test several mechanistic concepts of VlsE-mediated immune evasion. This 3-year research project, starting on May 1, 2024 and ending on April 30, 2027, aims to advance the understanding of Lyme disease pathogenesis and inform the development of new diagnostic tools and treatment strategies. As a public research institution, Washington State University will leverage its expertise in microbiology, genomics, and laboratory testing to conduct this innovative, high-impact research with potential applications for improving military and public health.
Generated 1/14/25, 6:06 AM